Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma

被引:9
作者
Minematsu, Tsuyoshi [1 ]
Felder, Laurie [2 ]
Oppeneer, Todd [2 ]
Sakazume, Masashi [3 ]
Oikawa, Keishi [4 ]
Hashimoto, Tadashi [1 ]
Usui, Takashi [1 ]
Kamimura, Hidetaka [1 ]
机构
[1] Astellas Pharma Inc, Drug Metab Res Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Covance Labs Inc, Madison, WI USA
[3] Astellas Res Technol Co Ltd, Tokyo, Japan
[4] Astellas Pharma Inc, Clin Pharmacol, Tokyo, Japan
关键词
YM155; bioanalytical method; LC-MS/MS; validation; pharmacokinetics; dog plasma;
D O I
10.1002/bmc.996
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a sensitive and selective liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for determination of the novel survivin suppressant YM155, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, which is developed for the treatment of solid tumors. This method uses a liquid-liquid extraction from 0.25 mL of dog plasma. LC separation was carried out on a Genesis Silica column (50 mm x 3.0 mm i.d.) at a flow-rate of 0.5 mL/min. Compounds were eluted using a mobile phase of 5 mm ammonium acetate and 0.1% formic acid in water-0.1% formic acid in acetonitrile, 17:83 (v/v). MS/MS detection was carried out with an MDS-Sciex API3000 triple quadrupole mass spectrometer in positive electrospray ionization mode. The standard curve was linear from 0.05 to 50 ng/mL (r >= 0.9968). The lower limit of quantitation was 0.05 ng/mL. Good intra- and inter-day assay precision (within 7.4% RSD) and accuracy (within +/- 12.3%) were obtained. The extraction recovery was 66.2%. The method was successfully applied to preelinical pharmacokinetic studies in dogs. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 21 条
[1]   Anti-apoptosis gene, survivin, and prognosis of neuroblastoma [J].
Adida, C ;
Berrebi, D ;
Peuchmaur, M ;
Reyes-Mugica, M ;
Altieri, DC .
LANCET, 1998, 351 (9106) :882-883
[2]   A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma [J].
Ambrosini, G ;
Adida, C ;
Altieri, DC .
NATURE MEDICINE, 1997, 3 (08) :917-921
[3]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[4]   Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors:: implication of survivin expression in normal hematopoiesis [J].
Fukuda, S ;
Pelus, LM .
BLOOD, 2001, 98 (07) :2091-2100
[5]  
Giodini A, 2002, CANCER RES, V62, P2462
[6]   High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J].
Islam, A ;
Kageyama, H ;
Takada, N ;
Kawamato, T ;
Takayasu, H ;
Isogai, E ;
Ohira, M ;
Hashizume, K ;
Kobayashi, H ;
Kaneko, Y ;
Nakagawara, A .
ONCOGENE, 2000, 19 (05) :617-623
[7]   Escaping cell death:: Survival proteins in cancer [J].
Jäättelä, M .
EXPERIMENTAL CELL RESEARCH, 1999, 248 (01) :30-43
[8]   YM155, a novel small molecule survivin suppressant, exhibits curative antitumor activities in experimental human malignant lymphoma models in vivo [J].
Kita, A. ;
Nakahara, T. ;
Yamanaka, K. ;
Koutoku, H. ;
Takeuchi, M. ;
Kinoyama, I. ;
Matsuhisa, A. ;
Sasamata, M. .
EJC SUPPLEMENTS, 2006, 4 (12) :116-116
[9]  
Lu CD, 1998, CANCER RES, V58, P1808
[10]   A novel anti-apoptosis gene:: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers [J].
Monzó, M ;
Rosell, R ;
Felip, E ;
Astudillo, J ;
Sánchez, JJ ;
Maestre, J ;
Martín, C ;
Font, A ;
Barnadas, A ;
Abad, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2100-2104